个人简介
1999~2003:武汉大学药学院药学系,获学士学位;
2003~2006:武汉大学药学院药剂系,获硕士学位;
2006~2009:北京大学药学院药剂学专业,获博士学位;
2009~2012:北京大学基础医学院,博士后;
2012~今,北京大学药学院药剂学系,助理研究员
研究领域
基于药物递送技术的肿瘤联合治疗;基于肿瘤微环境调控的纳米药物递送研究;难溶性药物创新制剂研发
近期论文
查看导师新发文章
(温馨提示:请注意重名现象,建议点开原文通过作者单位确认)
1. Wenbing Dai, Xiaoyou Wang, Ge Song, Tongzhou Liu, Bing He, Hua Zhang, Xueqing Wang, Qiang Zhang*. Combination antitumor therapy with targeted dual-nanomedicines. Adv Drug Deliv Rev . 2017, 115, 23-45.
2. Binlong Chen, Wenbing Dai*, Bing He, Hua Zhang, Xueqing Wang, Yiguang Wang, Qiang Zhang*. Current Multistage Drug Delivery Systems Based on the Tumor Microenvironment. Theranostics . 2017, 7(3): 538-58.
3. Wenbing Dai#, Fang Yang#, Ling Ma, Yuchen Fan, Bing He, Qihua He, Xueqing Wang, Hua Zhang, Qiang Zhang*. Combined mTOR inhibitor rapamycin and doxorubicin-loaded cyclic octapeptide modified liposomes for targeting integrin α3 in triple-negative breast cancer. Biomaterials , 2014, 35(20):5347-5358.
4. Binlong Chen#, Wenbing Dai#*, Dong Mei, Tongzhou Liu, Suxin Li, Bo He, Bing He, Lan Yuan, Hua Zhang, Xueqing Wang, Qiang Zhang*. Comprehensively priming the tumor microenvironment by cancer-associated fibroblast-targeted liposomes for combined therapy with cancer cell-targeted chemotherapeutic drug delivery system. J Control Release . 2016, 241(10): 68-80.
5. Zhiqiang Lin, Dong Mei, Meiwan Chen, Yitao Wang, Xianhui Chen, Zhaoyang Wang,Bing He, Hua Zhang, Xueqing Wang, Wenbing Dai*, Yuxin Yin*, Qiang Zhang*. A comparative study of thermo-sensitive hydrogels with water-insoluble paclitaxel in molecule, nanocrystal and microcrystal dispersions. Nanoscale . 2015, 7(36): 14838-47.
6. Binlong Chen, Zhaoyang Wang, Jing Sun, Qin Song, Bing He, Hua Zhang, Xueqing Wang, Wenbing Dai*, Qiang Zhang*. A tenascin C targeted nanoliposome with navitoclax for specifically eradicating of cancer-associated fibroblasts. Nanomedicine . 2016, 12(1): 131-41.